Loading stock data…
Cytek Biosciences, Inc. (CTKB)
$4.62-0.08 (-1.70%)
Market ClosedLast close Sep 8
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytek Biosciences, Inc. in the Healthcare sector is trading at $4.62 with a market capitalization of $602M. Wall Street consensus targets $5.56 (4 analysts), implying a +20.4% move over the next 12 months. The stock is currently 25% below its 52-week high of $6.18, remaining 0.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $48.14M↑ | $44.13M↓ | $62.14M↑ | $52.29M↑ | $45.60M |
| Gross Profit | $28.34M↑ | $21.25M↓ | $32.88M↑ | $27.55M↑ | $23.87M |
| Operating Income | -$11.40M↑ | -$18.46M↓ | -$5.59M↑ | -$9.19M↑ | -$10.62M |
| Net Income | -$12.16M↑ | -$18.87M↑ | -$44.08M↓ | -$5.48M↑ | -$5.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$602.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.03%
Volume
Today's trading volume
648,684
Recent News
Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing
On August 5, Cytek Biosciences (NASDAQ:CTKB) reported financial results for the second quarter ended June 30, and the report reads like two different companies at once. Revenue climbed, margins widened, and the installed base of instruments kept expanding. At the same time, the net loss more than doubled from a year earlier and adjusted EBITDA […]
Cytek (CTKB) Q2 2026 Earnings Call Transcript
U.S. revenue surged 18% while EMEA declined 8% amid geopolitical pressures.
Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary
Moby summary of Cytek Biosciences, Inc.'s Q2 2026 earnings call
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...
Cytek Biosciences Inc (CTKB) delivers solid Q2 2026 results with 6% revenue growth, launches the industry-first Borealis 60-color system, and raises full-year guidance despite EMEA softness.
Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences (NASDAQ:CTKB) reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth. Revenue for the quarter ended June 30 was $48.1 mill